医保支付方类型预测B型主动脉夹层急诊TEVAR临床表现与死亡率
基于VQI数据库2011-2021年1862例非择期TEVAR的B型主动脉夹层患者,比较政府医保与商业医保两组的临床表现和结局。政府医保组主动脉破裂率更高(12.5% vs 7.8%),术后住院、30天和1年死亡率均更高(9.7% vs 5.3%、9.8% vs 5.9%、18% vs 10%,均P<0.05),脊髓缺血风险翻倍(5% vs 2.4%)。
要点
- 政府医保患者非择期TEVAR时主动脉破裂率更高(12.5% vs 7.8%)。
- 政府医保组术后住院死亡率9.7% vs 商业医保5.3%(P<0.05)。
- 政府医保组术后脊髓缺血风险翻倍(5% vs 2.4%)。
核心结论
- 政府医保患者因B型主动脉夹层行非择期TEVAR时疾病更晚期且结局更差。
- 结果提示医疗可及性差异,需针对性改善弱势人群的慢病管理和术后护理。
研究设计与样本
- 回顾性队列研究,使用血管外科学会VQI数据库2011-2021年数据。
- 纳入所有因B型主动脉夹层行非择期TEVAR的患者,共1862例。
- 按医保类型分两组:政府医保组960例(51.6%),商业医保组902例(48.4%)。
- 亚组分析比较政府医保组内Medicare与Medicaid受者结局。
主要发现
- 政府医保组主动脉破裂率12.5% vs 商业医保组7.8%。
- 政府医保组症状性疾病比例85% vs 商业医保组88.6%。
- 政府医保组术后住院死亡率9.7% vs 5.3%,30天死亡率9.8% vs 5.9%,1年死亡率18% vs 10%(均P<0.05)。
- 政府医保组出院时脊髓缺血5% vs 2.4%,呼吸系统并发症14.4% vs 10.8%。
临床怎么用
- 对政府医保的B型主动脉夹层患者应加强血压等慢病管理以预防夹层发生。
- 非择期TEVAR围术期需警惕政府医保患者更高的破裂、死亡和脊髓缺血风险。
- 术后应强化政府医保患者的随访和并发症监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Socioeconomic disparities influence access to care and outcomes across vascular surgery. Type B aortic dissection (TBAD) frequently results from uncontrolled hypertension and may present emergently in patients with limited health-care access. This study examines the impact of health-care insurance payor type as a surrogate for socioeconomic status on outcomes of nonelective (urgent/emergent) thoracic endovascular aortic repair (TEVAR) in patients with complicated TBAD. Given that TBAD often results from uncontrolled hypertension, patients with lower socioeconomic status may experience delayed diagnosis and suboptimal preventive care. METHODS: The Society for Vascular Surgery Vascular Quality Initiative database was explored from 2011 to 2021. All patients receiving nonelective TEVAR for TBAD were included. Patients were stratified into 2 groups: group I included patients on federal or state-funded insurance programs (Medicare, Medicaid, or Medicare advantage) and group II comprised of patients on commercial insurance plans. Analysis was performed to compare the disease characteristics and postoperative outcomes between the 2 groups. A subgroup analysis was also performed within the government-insured cohort to compare outcomes between Medicare and Medicaid recipients. RESULTS: A total of 1,862 patients were analyzed, of which 960 (51.6%) were in group I and 902 (48.4%) were categorized in group II. Patients in group I on federal or state-funded health-care insurance programs were presented with much higher rates of ruptured aorta (12.5% vs. 7.8%) and lower rates of symptomatic disease (85% vs. 88.6%) when compared to group II. Group I was also seen to have higher postoperative inhospital mortality (9.7% vs. 5.3%), 30-day (9.8% vs. 5.9%), and 1-year mortality (18% vs. 10%) when compared to group II (all P < 0.05). Group I patients were also observed to have twice the risk of postoperative spinal ischemia at discharge (5% vs. 2.4%) when compared to their counterparts. A similar trend of adverse respiratory complications (14.4% vs. 10.8%) was seen in group I. CONCLUSION: Patients with government-funded insurance undergoing nonelective TEVAR for TBAD present with more advanced disease and experience worse outcomes compared to patients with commercial insurance coverage. These findings highlight critical health-care disparities and underscore the need for targeted strategies to improve access, chronic disease management, and postoperative care in vulnerable populations.
引用
- Zil-E-Ali A, So KL, Choi ES, et al. Health Insurance Payor Type as a Predictor of Clinical Presentation and Mortality in Patients Undergoing Urgent or Emergent TEVAR for Type B Aortic Dissection: Insights from Society for Vascular Surgery Vascular Quality Initiative Database. Ann Vasc Surg. 2026. PMID: 41692161. doi:10.1016/j.avsg.2026.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。